Loading...
Please wait, while we are loading the content...
Similar Documents
Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors
| Content Provider | Scilit |
|---|---|
| Author | Berzaczy, Dominik Giraudo, Chiara Haug, Alexander R. Raderer, Markus Senn, Daniela Karanikas, Georgios Weber, Michael Mayerhoefer, Marius E. |
| Copyright Year | 2017 |
| Description | Journal: Clinical nuclear medicine The aim of this study was to assess the diagnostic performance of simultaneous whole-body 68Ga-DOTANOC PET/MRI compared with 68Ga-DOTANOC PET/CT for detection of distant metastatic disease in patients with well-differentiated neuroendocrine tumors (NETs). Patients with histologically proven, well-differentiated NET (G1 or G2) were included in this prospective, institutional review board–approved study. Patients underwent 68Ga-DOTANOC PET/CT and subsequent 68Ga-DOTANOC PET/MRI after a single tracer injection on the same day for staging or restaging purposes. Images were evaluated for the presence of NET lesions by 2 rater teams, each consisting of a nuclear medicine physician and a radiologist, in an observer-blinded fashion. Overall agreement, accuracy, sensitivity, and specificity, relative to a composite reference standard (consensus review including follow-up data), were calculated. Between July 2014 and June 2016, 28 patients were enrolled. Overall agreement and accuracy between the 2 rater teams were 91.7% (95% confidence interval [CI], 87.5%–95.9%) and 97% (95% CI, 94.4%–99.6%) for PET/MRI and 92.3% (95% CI, 88.3%–96.3%) and 94.6% (95% CI, 91.2%–98.1%) for PET/CT, respectively (P = 1.00). Overall, PET/MRI reached 89.8% sensitivity (95% CI, 77.8%–96.6%) and 100% specificity (95% CI, 97%–100%); PET/CT showed 81.6% sensitivity (95% CI, 68%–91.2%) and 100% specificity (95% CI, 97%–100%) for the detection of metastatic disease in NETs. Whole-body 68Ga-DOTANOC PET/MRI appears to be comparable to 68Ga-DOTANOC PET/CT for lesion detection in patients with well-differentiated NETs. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
| Related Links | http://europepmc.org/articles/pmc5636054?pdf=render https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636054/pdf http://ssr-eus-go-csi.cloudapp.net/v1/assets?wkmrid=JOURNAL/cnum/beta/00003072-900000000-97980/root/v/2017-07-22T190650Z/r/application-pdf |
| Ending Page | 674 |
| Page Count | 6 |
| Starting Page | 669 |
| ISSN | 03639762 |
| e-ISSN | 15360229 |
| DOI | 10.1097/rlu.0000000000001753 |
| Journal | Clinical nuclear medicine |
| Issue Number | 9 |
| Volume Number | 42 |
| Language | English |
| Publisher | Ovid Technologies (Wolters Kluwer Health) |
| Publisher Date | 2017-09-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Clinical nuclear medicine Radiology, Nuclear Medicine and Imaging 68ga-dota Peptides Computed Tomography Magnetic Resonance Imaging Neuroendocrine Tumors Positron Emission Tomography |
| Content Type | Text |
| Resource Type | Article |
| Subject | Radiology, Nuclear Medicine and Imaging |
